Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents

Biondi‐Zoccai, Giuseppe; Garmendia, Cristian; Abbate, Antonio; Giordano, Arturo; Frati, Giacomo; Sciarretta, Sebastiano; Antonazzo, Barbara; Versaci, Francesco

doi:10.1007/s11883-020-0819-1

Cited by 10 publications

(8 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After correction for body weight, no clinically significant disease status, gender, or age-related successfully with anakinra [25,26] Dose: 1-2 mg/kg/day (up to 100 mg/day). Overall, no serious side effects were observed in this patient population [27] No data on the efficacy and safety of IL-1 inhibitors during pregnancy Case series; Case reports; RCT (AIRTRIP trial) [24] The IRAP (International Registry of Anakinra for Pericarditis) study [28] 54 $ Canakinumab Recurrent rheumatic disease-associated pericarditis:…”

Section: Canakinumabmentioning

confidence: 96%

“…Anakinra has been widely used in cardiovascular settings to tackle conditions such as pericardial disease, heart failure, coronary artery disease, and myocardial infarction [9,24,28,38]. After the first reports and case series, anakinra (100 mg die) was studied in a double-blind, placebo-controlled trial in patients with colchicine-resistant and corticosteroiddependent IRP (the AIRTRIP trial) [39••].…”

Section: Anakinramentioning

confidence: 99%

See 1 more Smart Citation

Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020

et al. 2020

View full text Add to dashboard Cite

Recent advances have shown impressive results by anti-interleukin 1 (IL-1) agents in refractory idiopathic recurrent pericarditis. Purpose of ReviewWe critically discuss the current state of the art of therapy of relapsing pericarditis, with a focus on new pharmacological approaches and on specific clinical settings such as pregnancy, pediatric patients, and secondary forms of relapsing pericarditis. Recent FindingsAntagonism of the IL-1 is highly effective in idiopathic recurrent pericarditis with autoinflammatory features. Currently, available anti-IL-1 agents are anakinra and canakinumab. Rilonacept is another IL-1 antagonist, currently studied in the phase-3 clinical trial RHAPSODY. Available data suggest similar efficacy and safety profiles of these three agents, although only anakinra has been tested in randomized clinical trials. These agents have slightly different pharmacological properties, being canakinumab a specific IL-1ß antagonist while anakinra and rilonacept are unselective IL-1α and IL-1ß blockers. To date, there is no evidence that specificity against IL-1ß affects safety and efficacy in patients with relapsing pericarditis, although it has been proposed that unspecific blockage might be useful in severe disease. Summary Anakinra is the first anti-IL-1 agent with well-documented efficacy and safety in adult and pediatric patients with idiopathic relapsing pericarditis. Other anti-IL-1 agents are currently under study. Future research should clarify the optimal duration of therapy and tapering schedule of treatment with these agents. Moreover, biomarkers would be required to understand which patients will benefit from early administration of IL-1 blockers due to refractoriness to conventional therapy and which others will suffer from recurrences during the tapering of these agents. Lastly, future studies should focus on the subjects with the autoimmune or the pauci-inflammatory phenotype of idiopathic refractory pericarditis.

show abstract

Section: Canakinumabmentioning

confidence: 96%

Section: Anakinramentioning

confidence: 99%

Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020

et al. 2020

View full text Add to dashboard Cite

show abstract

“…A local expression of IL-1α by endothelial cells promotes thrombosis by recruiting granulocytes to the lung[ 94 ]. Relying on this concept, the IL-1 blockade might avert thromboembolic events in COVID-19[ 95 ]. On the other hand, an IL-1 receptor antagonist (IL-1Ra) can limit inflammatory reactions and tissue damage during ARDS.…”

Section: The Potential Role Of Il-1 In Crsmentioning

confidence: 99%

COVID-19 infection: an overview on cytokine storm and related interventions

Montazersaheb

Khatibi

Hejazi

et al. 2022

Virol J

263

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has posed a significant threat to global health. This virus affects the respiratory tract and usually leads to pneumonia in most patients and acute respiratory distress syndrome (ARDS) in 15% of cases. ARDS is one of the leading causes of death in patients with COVID-19 and is mainly triggered by elevated levels of pro-inflammatory cytokines, referred to as cytokine storm. Interleukins, such as interleukin-6 (1L-6), interleukin-1 (IL-1), interleukin-17 (IL-17), and tumor necrosis factor-alpha (TNF-α) play a very significant role in lung damage in ARDS patients through the impairments of the respiratory epithelium. Cytokine storm is defined as acute overproduction and uncontrolled release of pro-inflammatory markers, both locally and systemically. The eradication of COVID-19 is currently practically impossible, and there is no specific treatment for critically ill patients with COVID-19; however, suppressing the inflammatory response may be a possible strategy. In light of this, we review the efficacy of specific inhibitors of IL6, IL1, IL-17, and TNF-α for treating COVID-19-related infections to manage COVID-19 and improve the survival rate for patients suffering from severe conditions. Graphical Abstract

show abstract

“…It helps sensing damage and provides an inflammatory response through activation of caspase‐1 and the production and release of pro‐inflammatory cytokines, such as interleukin (IL)‐1β and IL‐18 23 . Nonetheless, the NLRP3 inflammasome is being studied as a therapeutic target in preclinical and clinical studies to tackle the detrimental consequences of ACS 24 and stroke 25 …”

Section: Figurementioning

confidence: 99%